GlassScriptPhysician profile
Jonathan Clavell Hernandez
NPI 1619230869
$500,243.93
in general payments reported to CMS, 2019-2025
24 companies · $104K in 2025
The $104K reported for 2025 was more than what 99% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $23K · 2021: $40K · 2022: $101K · 2023: $130K · 2024: $87K · 2025: $104K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $229K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $68K · Food and Beverage: $17K · Travel and Lodging: $6,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $229,075.46 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $67,859.00 |
| Food and Beverage | $17,448.21 |
| Travel and Lodging | $6,050.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $314,172.06 | 2019-2025 | Titan |
| Boston Scientific Corporation | $166,159.00 | 2019-2025 | Ams 700 Cxr Rte Kit, General - Erectile Dysfunction, Ams 700 |
| Endo Pharmaceuticals INC. | $16,674.76 | 2019-2024 | Xiaflex, Aveed |
| Astellas Pharma US INC | $820.70 | 2019-2024 | Xtandi, Myrbetriq |
| Pfizer INC. | $558.95 | 2019-2023 | |
| Endo USA, INC. | $432.47 | 2024-2025 | Xiaflex, Aveed |
| Antares Pharma, INC. | $340.90 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Verity Pharmaceuticals INC. | $183.10 | 2021-2024 | Trelstar |
| Axonics, INC. | $175.11 | 2020-2021 | |
| Valencia Technologies Corporation | $127.49 | 2025 | Ecoin Device Kit |
| Convatec INC. | $89.54 | 2019-2020 | |
| Acerus Pharmaceuticals Corporation | $71.15 | 2020-2022 | |
| Tolmar, INC. | $68.62 | 2023-2025 | Jatenzo |
| Angiodynamics, INC. | $64.69 | 2023 | Solero, Nanoknife |
| Ferring Pharmaceuticals INC. | $57.43 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $39.46 | 2021-2025 | Urolift |
| 180 Medical, INC. | $38.82 | 2019-2022 | |
| Neotract INC. | $33.48 | 2020 | |
| Innovation Technologies INC | $33.12 | 2022 | |
| Mission Pharmacal Company | $28.66 | 2019-2020 | |
| Olympus America INC. | $24.38 | 2019 | |
| Abbvie INC. | $17.91 | 2024 | |
| Halozyme INC | $16.44 | 2023 | |
| Duchesnay USA Incorporated | $15.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Clavell Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.